Arcturus Therapeutics, Inc.

This study tested a new type of COVID-19 vaccine (ARCT-2303) in about 1,500 adults who had already received a COVID-19 vaccine. Some participants got the COVID vaccine and the flu shot at the same time, while others got only the COVID vaccine. The goal was to see if the new vacci…

This early-stage study tested a new type of seasonal flu vaccine called ARCT-2138, which uses self-amplifying mRNA technology to potentially boost immune responses. Researchers gave the vaccine to 139 healthy adults aged 18-49 and 65-85 to check for side effects and measure antib…

This study tested three new self-amplifying RNA vaccines against COVID-19 in 72 healthy adults, including some who had already been vaccinated and some who had not. The main goals were to check safety and measure the immune response. The vaccines were designed to help the body fi…

This study tested a new self-amplifying mRNA vaccine (ARCT-2304) designed to protect against a future pandemic flu. 212 healthy adults aged 18-80 received either the experimental vaccine or a licensed flu shot. Researchers monitored side effects and measured immune responses to f…